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ORIGINAL ARTICLE
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ABSTRACT
Background: Older people have the highest incidence of melanoma and the population in most
Western countries is ageing. We evaluated how the gap in incidence and survival between younger
and older patients has developed during the past decades.
Material and methods: All patients diagnosed with cutaneous melanoma between 1989 and 2015
(n¼ 84,827) were identified from the Netherlands Cancer Registry. Elderly were defined as aged 70
years. Differences in patient and tumor characteristics were described, age-specific incidence rates
were calculated, and relative survival (RS) and multivariable analyses estimating the Relative Excess
Rate of dying (RER) were conducted
Results: In older men, the melanoma age-standardized incidence increased from 18 to 103/100,000
person-years (py) between 1989 and 2015 and in older women from 23 to 70/100,000 py. In younger
men and women, it increased from 8 to 21 and from 13 to 28/100,000 py, respectively. Median
Breslow thickness declined from 1.8 to 1.1mm and from 1.6 to 1.1mm in older men and women
(2003 versus 2015), and from 1.1 to 0.9mm and 0.9 to 0.8mm in younger men and women. In older
men, 5-year RS increased from 67% (95% CI: 63%–72%) in 1989–1997 to 85% (95% CI: 83%–87%) in
2007–2015 and in older women from 81% (95% CI: 78%–85%) to 89% (95% CI: 87%–91%). In younger
men and women, RS increased from 82% (95% CI: 81%–83%) to 90% (95% CI: 90%–91%) and from
92% (95% CI: 92%–93%) to 96% (95% CI: 95%–96%). After case-mix correction , older men and women
no longer showed an improved survival over time (RER 2010–2015 versus 2003–2009: 0.97; 95% CI:
0.81–1.16 and 0.95; 95% CI: 0.79–1.16). Whereas in younger men and women survival remained
improved (RER 0.75; 95% CI: 0.67–0.83 and 0.77; 95%CI: 0.67–0.89).
Conclusion: The gap in melanoma incidence between younger and older people is increasing due to
a strong increase in incidence in older adults. Disparities in survival are declining, related to a narrow-
ing gap in Breslow thickness.
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Introduction
While cutaneous melanoma is one of the cancer sites with a
rather high risk among younger persons, the risk of being
diagnosed with a melanoma is still considerably higher
among older persons.
The Netherlands currently ranks third in terms of melan-
oma incidence in Europe, and its incidence is still increasing
[1,2]. Like many other Western countries, the population is
ageing. During the next decade, the number of elderly (aged
65 years) is expected to rise with 30% [3]. Due to the age-
ing population and the higher risk of melanoma seen in
older people, a fast-growing group of older melanoma
patients will be encountered in clinical practice in the
near future.
Being diagnosed at an older age is generally a poor prog-
nostic factor in cancer. The worse prognosis of older patients
is related to a late diagnosis, presence of more poor histo-
logical features, less treatments offered or used by patients
and a higher number of comorbidities or lower performance
score compared to younger patients [4–9].
Despite the growing number of older patients, most clin-
ical trials are still focused on the younger and more fit
patients. If older patients are included, they are usually not
representative for the entire cohort of older cancer patients.
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Consequently, the knowledge concerning the safety and effi-
cacy of treatment regimes in older patients is often limited.
With this nationwide study, we aim to provide insight
into the burden of melanoma in elderly patients. Besides, we
will evaluate how the gap in incidence and survival has
developed during the last three decades and relate this to
changes in patient and tumor characteristics.
Material and methods
Patient selection
Patients were identified from the Netherlands Cancer Registry
(NCR). The NCR is a population-based registry based on notifi-
cation by the automated nationwide network and registry of
histo- and cytopathology in the Netherlands (PALGA), and
complemented by other sources such as national registry of
hospital discharge and radiotherapy institutes. This compre-
hensive registry covers the entire Dutch population.
After notification, fully trained registry clerks routinely
extract data on patient and tumor characteristics and treat-
ment from pathology reports and patients’ files in all Dutch
hospitals. Information on vital status (alive, emigrated or
dead) and date of death or emigration is annually retrieved
from the database of deceased persons of the Central
Bureau of Genealogy and the municipal demography regis-
tries (GBA).
Topography and Morphology are coded according to the
International Classification of Diseased for Oncology [10,11]
and tumor stage according to Tumor-Node-Metastasis (TNM)
classification (International Union Against Cancer, 6th
(2003–2009) and 7th (2010–2015) edition) [12,13]. The patho-
logical T, N and M stage was used and supplemented by
information of the clinical stage in case pathological stage
was not available. For overall TNM stage, we assumed that if
no information on lymph node or distant metastases status
was recorded in a patient’s medical file they were negative.
Comorbidities were routinely collected for patients diag-
nosed the southern part of the Netherlands and recorded
according to a slightly adapted version of the Charlson classi-
fication [14,15].
For this study, all consecutive patients diagnosed with a
primary invasive cutaneous melanoma in the Netherlands
between 1989 and 2015 were selected from the NCR.
Patients diagnosed at autopsy were excluded (n¼ 168).
Variables that were selected from the NCR included age at
diagnosis, histology (nodular melanoma (NM)/superficial
spreading melanoma (SSM)/lentigo maligna melanoma
(LMM) and other/unspecified), Breslow thickness, TNM stage,
lymph node status (positive/negative/unknown), number of
comorbidities and vital status. We chose to define older
patients as aged 70 years at time of diagnosis because
age-specific incidence rates peaked at the age of 70 [1].
Statistical analyses
Trends in melanoma incidence were analyzed by calculating
annual age-standardized incidence rates by age category
(<70 years (younger) and 70 years (older)), and age-specific
incidence rates (5-year age categories) by three equal time
periods (1989–1997, 1998–2006, 2007–2015). For age stand-
ardization, we used the 2000 Dutch population (stratified by
<70 and 70 years) as standard. All analyses were stratified
by sex. Changes in incidence were evaluated by calculating
the estimated annual percentage changes (EAPCs) and their
corresponding 95% confidence intervals (CI). To calculate
this, a regression line was fitted to the natural logarithm of
the rates, using the calendar year as regressor variable [i.e.,
y¼ axþb where y¼ ln(rate) and x¼ calendar year, then
EAPC¼ 100  (ea1)].
Differences in tumor and patient characteristics between
age groups (<70, 70–79, 80–89 and 90 years) and between
time periods (2003–2009 versus 2010–2015) in older patients
were evaluated using chi-square tests and Wilcoxon Rank
sum tests. These analyses were performed from 2003
onwards because of changes in TNM classification and the
availability of Breslow thickness in the NCR. Subgroup analy-
ses including comorbidities were performed since comorbid-
ities were only routinely collected in the South Eastern
region of the Netherlands (n¼ 6980, 12% of the
study population).
A graph of the median Breslow thickness per year and
age category was constructed to show the trends over time.
Median Breslow thickness was smoothed by calculating the
three-year moving averages in order to demonstrate time
trends more clearly.
To obtain an estimation of disease-specific survival, we
calculated one- to five-year relative survival (RS) according to
the Ederer II method [16]. In the RS analyses, the ratio of
observed to the expected survival based on a sex, age and
calendar year matched population was calculated. Survival
time was defined as date of diagnosis to date of death, emi-
gration or until 1 January 2018, whichever came first.
Analyses were stratified by period of diagnosis and sex, or
by stage at diagnosis.
To identify the effect of age on excess mortality (relative
excess risk of dying (RER)) due to melanomas and to identify
factors associated with excess mortality in younger and older
patients, we performed multivariable regression models
using the Poisson generalized linear model framework. In
these models, we included the log-transformed
Breslow thickness.
All analyses were performed using STATA/SE 14.1
(StataCorp, College Station, TX, USA). A two-sided p value of
<.05 was considered statistically significant.
Results
A total of 84,827 patients with invasive cutaneous melanoma
diagnosed between 1989 and 2015 were identified from the
NCR, 19,507 (23%) of them were aged 70 years at time of
diagnosis. The proportion of older patients increased from
17% in 1989 to 29% in 2015. Median age at diagnosis
increased with 11 years (from 50 years to 61 years) during
the same calendar period.
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Trends in incidence
Figure 1 shows age-standardized incidence rates/100,000
person-years (py) of melanoma by sex and age category
(<70 years and 70 years) between 1989 and 2015.
An increase in incidence was seen among all groups. In
younger men and women (<70 yr), age-standardized inci-
dence increased steadily, whereas older men showed the
steepest increase with an EAPC of 7.0% (95% CI: 6.8%–7.3%).
In 2015, their incidence rate was nearly 6 times higher com-
pared to 1989. In older women (70 yr), incidence increased
threefold during the same time period with an EAPC of 5.2%
(95% CI: 5.0%–5.3%).
Incidence rates, by 5-year age categories and period of
diagnosis, showed an increasing incidence in nearly all age
categories (in both men and women). The incidence
increased most between the two most recent time periods
(2007–2015 versus 1998–2006) (Supplementary Figure 1). In
2007–2015, age-specific incidence rates in women stabilized
after the age of 65 years with an incidence rate around 60/
100,000 py. In men, age-specific incidence rates continued to
increase with advancing age and peaked at 97/100,000 py in
men aged 85 years.
Patient- and tumor characteristics by age category
With advancing age, the proportion of patients diagnosed
with thicker melanomas (Breslow thickness >2mm) increased
(Table 1). Also more older patients had an unknown Breslow
thickness. SSM was the most frequently diagnosed histo-
logical subtype among all age categories in both men and
women, but the proportion decreased with advancing age.
NM and LMM were more frequently seen with increasing age
in both sexes.
In younger male patients, most melanomas (54%) were
seen at the trunk, and 12% was located at the head or neck.
Contrary, in the oldest male patients (90 yr) most melano-
mas (58%) were seen at the head and neck, and only 24%
was diagnosed at the trunk. The most common site for
melanomas in younger females was the lower limbs (38%),
while 7% was located at the head or neck. In the oldest age
category (90 yr), the predominant location was the head
and neck (39%) and fewer melanomas were found at the
lower limbs (27%).
Time trends of patient- and tumor characteristics of
older melanoma patients
In both older men and women, period of diagnosis was stat-
istically significantly associated with Breslow thickness, tumor
localization, histological subtype and lymph node status
(Table 2). In the more recent years (2010–2015 versus
2003–2009), older men and women were more often diag-
nosed with thin (<1mm) melanomas, and with truncal mela-
nomas. The proportion of SSM increased from 48 to 69% in
older men, and from 47 to 57% in older women. Lymph
node status was more often known over time, with more
patients having a negative lymph node status (63% in
2003–2009 versus 71% in 2010–2015 for both men and
women). Whereas period of diagnosis was statistically signifi-
cantly associated with distant metastases (p¼ .03) in older
women, we did not find an association in older men (p¼ .3).
Median Breslow thickness declined strongly in older
patients (Figure 2). In 2003, the median Breslow thickness of
older men was 1.8mm (Interquartile range (IQR): 0.9–4.0mm)
versus 1.1mm (IQR: 0.6–2.6mm) in 2015. In older women,
the median Breslow thickness decreased from 1.6mm (IQR:
0.7–3.8mm)) to 1.1mm (IQR: 0.5–2.5mm). During the same
time period, Breslow thickness decreased with 0.2mm in
younger men (from 1.1 (IQR: 0.7–1.3mm) to 0.9mm (IQR:
0.5–1.7mm)) and 0.1mm in younger women (from 0.9mm
(IQR: 0.6–1.5mm) to 0.8mm (IQR: 0.5–1.3mm)).
Survival
Older patients showed worse RS compared to younger
patients (Supplementary Figure 2). Over time, survival
Figure 1. Age-standardized incidence rates of cutaneous melanoma, by age category and sex (1989–2015).
Rates are age-standardized using the 2000 Dutch Population. CI: confidence interval; EAPC: estimated annual percentage change.
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improved in all patients. The improvements were largest in
older men, but also started at a lower level. Their 5-year RS
increased from 67% (95% CI: 63%–72%) in 1989–1997 to
85% (95% CI: 83%–87%) in 2007–2015. In older women, 5-
year RS increased from 81% (95% CI: 78%–85%) to 89% (95%
CI: 87%–91%) between the same time periods. Also in
younger patients survival improved, but differences in sur-
vival between younger and older patients declined over
time. In men, the gap declined from a 15 percentage point
(pp) difference in 1989–1997 to a 5 pp difference in
2007–2015, and in women from a 11 to a 7 pp difference,
respectively.
Compared to younger patients, RS by TNM stage revealed
poorer outcomes of older patients diagnosed with a stage II,
III or unknown stage melanoma, but not for patients with a
stage I or IV melanoma (2003–2015) (Supplementary
Figure 3). Survival of stage I melanoma slightly exceeded the
survival of the general population in older patients, whereas
it approached the general population’s survival in
younger patients.
In multivariable survival analysis (adjusted for sex, histo-
logical subtype, localization, Breslow thickness, lymph node
status and distant metastases), age was identified as an
adverse prognostic factor (RER 80 years versus <70 years:
2.21; 95% CI: 1.92–2.55) (data not shown). Analyses stratified
by age category showed a statistically significantly lower RER
of dying in the most recent time period in younger patients.
In older patients also a lower RER was seen in the univariable
analyses, however, this association disappeared after adjust-
ment for other prognostic factors (Table 3).
Analyses were repeated with only period of diagnosis and
Breslow thickness entered into the models. Also in these
models, period of diagnosis was no longer associated with
excess mortality (2003–2009 versus 2010–2015) in both older
men (RER 0.97; 95% CI: 0.81–1.16) and older women (RER
0.99; 95% CI: 0.83–1.12) (data not shown).






<70 years 70–79 years 80–89 years 90 years <70 years 70–79 years 80–89 years 90 years
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
N 18,793 4663 1995 233 23,681 4341 2377 463
Breslow thickness <.001 <.001
<1mm 9845 (52.4) 2099 (45.0) 741 (37.1) 66 (28.2) 14,815 (62.6) 2087 (48.1) 789 (33.2) 93 (20.1)
1.01–2mm 4233 (22.5) 931 (20.0) 338 (16.9) 29 (12.5) 5153 (21.8) 927 (21.4) 469 (19.7) 65 (14.0)
2.01–4mm 2608 (13.9) 857 (18.4) 415 (20.8) 53 (22.8) 2182 (9.2) 714 (16.5) 521 (21.9) 115 (24.8)
>4mm 1413 (7.5) 579 (12.4) 375 (18.8) 73 (31.3) 800 (3.4) 467 (10.8) 472 (19.9) 150 (32.4)
Unknown 694 (3.7) 197 (4.2) 126 (6.3) 12 (5.2) 731 (3.1) 146 (3.4) 126 (5.3) 40 (8.6)
Lymph nodes status <.001 <.001
N0 12,783 (68.0) 3229 (69.3) 1314 (65.9) 150 (64.4) 16,553 (69.9) 3018 (69.5) 1581 (66.5) 268 (57.9)
Nþ 1871 (10.0) 387 (8.3) 160 (8.0) 12 (5.2) 1326 (5.6) 283 (6.5) 174 (7.3) 42 (9.1)
Unknown 4139 (22.1) 1047 (22.5) 521 (26.2) 71 (30.5) 5802 (24.5) 1040 (24.0) 622 (26.2) 153 (33.1)
Distant metastasis at diagnosis .12 <.001
No 18,552 (98.7) 4585 (98.3) 1961 (98.3) 230 (98.7) 23,554 (99.5) 4297 (99.0) 2336 (98.2) 454 (98.1)
Yes 241 (1.3) 78 (1.7) 34 (1.7) 3 (1.3) 127 (0.5) 44 (1.0) 41 (1.7) 9 (1.9)
Histological subtype <.001 <.001
SSM 13,255 (70.5) 2808 (60.2) 938 (47.0) 89 (38.2) 17,675 (74.6) 2556 (58.9) 1094 (46.0) 140 (30.2)
NM 2266 (12.1) 744 (16.0) 400 (20.1) 66 (28.3) 2132 (9.0) 657 (15.1) 497 (20.9) 121 (26.1)
LMM 450 (2.4) 378 (8.1) 270 (13.5) 33 (14.2) 516 (2.2) 425 (9.8) 339 (14.3) 75 (16.2)
Other/unspecified 2822 (15.0) 733 (15.7) 387 (19.4) 4 (19.3) 3358 (14.2) 703 (16.2) 447 (18.8) 127 (27.4)
Tumor localization <.001 <.001
Head/neck 2272 (12.1) 1021 (21.9) 775 (38.9) 135 (57.9) 1748 (7.4) 769 (17.7) 650 (27.4) 180 (38.9)
Trunk 10,087 (53.7) 2186 (46.9) 653 (32.7) 56 (24.0) 7731 (32.7) 793 (18.3) 286 (12.0) 41 (8.9)
Upper limbs 3393 (18.1) 884 (19.0) 354 (17.7) 23 (9.9) 5256 (22.2) 1219 (28.1) 636 (26.8) 117 (25.3)
Lower limbs 2999 (16.0) 558 (12.0) 205 (10.3) 17 (7.3) 8891 (37.5) 1549 (35.7) 800 (33.7) 124 (26.8)
Unknown 42 (0.2) 14 (0.3) 8 (0.4) 2 (0.9) 55 (0.2) 11 (0.3) 5 (0.2) 1 (0.2)
TNM stage (6th and 7th ed.) <.001 <.001
I 13,139 (70.2) 2857 (61.3) 1022 (51.2) 86 (36.9) 19,152 (80.9) 2841 (65.5) 1166 (49.1) 140 (30.2)
II 3255 (17.3) 1261 (27.0) 723 (36.2) 121 (51.9) 2717 (11.5) 1099 (25.3) 937 (39.4) 244 (52.7)
III 1715 (9.1) 351 (7.5) 140 (7.0) 12 (5.2) 1237 (5.2) 260 (6.0) 153 (6.4) 39 (8.4)
IV 241 (1.3) 78 (1.7) 34 (1.7) 3 (1.3) 127 (0.5) 44 (1.0) 41 (1.7) 9 (1.9)
X 389 (2.1) 116 (2.5) 76 (3.8) 11 (4.7) 448 (1.9) 97 (2.2) 80 (3.4) 31 (6.7)
Period of diagnosisa <.001 <.001
2003–2009 8449 (77.9) 1660 (15.3) 679 (6.3) 58 (0.5) 11,139 (78.6) 1842 (13.0) 993 (7.0) 196 (1.4)
2010–2015 10,344 (69.7) 3003 (20.3) 1316 (8.9) 175 (1.2) 12,542 (75.1) 2499 (15.0) 1384 (8.3) 267 (1.6)
Subgroup analysis
Number of comorbiditiesb <.001 <.001
None 1435 (62.2) 144 (24.3) 33 (16.4) 2 (7.1) 2028 (68.9) 197 (36.8) 61 (24.7) 13 (24.1)
1 comorbidity 388 (16.8) 156 (26.3) 40 (19.9) 6 (21.4) 403 (13.7) 151 (28.2) 68 (27.5) 17 (31.5)
2 comorbidities 220 (9.5) 236 (39.8) 119 (59.2) 19 (67.9) 152 (5.2) 133 (24.9) 93 (37.7) 20 (37.0)
Unknown 265 (11.5) 57 (9.6) 9 (4.5) 1 (3.6) 359 (12.2) 54 (10.1) 25 (10.1) 4 (7.4)
aRow percentages are presented (instead of column percentages).
bData only available for a subgroup of the total study population (n¼ 6908, 12% of the total study population).
Abbreviations: LMM: lentigo maligna melanoma; NM: nodular melanoma; SSM: superficial spreading melanoma.
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N % N % N % N %
N 2397 4494 3031 4150
Median age in years arsywyears (IQR) 76 (73–81) 76 (73–81) .13 78 (73–83) 77 (73–83) .70
Breslow thickness <.001 <.001
<1mm 856 35.7 2050 45.6 1104 36.4 1865 44.9
1.01–2mm 460 19.2 838 18.7 626 20.7 835 20.1
2.01–4mm 507 21.2 818 18.2 583 19.2 767 18.5
>4mm 433 18.1 594 13.2 549 18.1 540 13.0
Unknown 141 5.9 194 4.3 169 5.6 143 3.5
Lymph node status <.001 <.001
N0 1508 62.9 3185 70.9 1902 62.8 2965 71.5
Nþ 206 8.6 353 7.9 220 7.3 279 6.7
Unknown 683 28.5 956 21.3 909 30.0 906 21.8
Distant metastasis .32 .03
No 2352 98.1 4424 98.4 2981 98.4 4106 98.9
Yes 45 1.9 70 1.6 50 1.7 44 1.1
TNM stage (6th and 7th ed.) <.001 <.001
I 1233 51.4 2732 60.8 1620 53.5 2527 60.9
II 843 35.2 1262 28.1 1059 34.9 1221 29.4
III 185 7.7 318 7.1 192 6.3 260 6.3
IV 45 1.9 70 1.6 50 1.7 44 1.1
Unknown 91 3.8 112 2.5 110 3.6 98 2.4
Histological subtype
SSM 1156 48.2 2679 59.6 <.001 1427 47.1 2363 56.9 <.001
NM 489 20.4 721 16.0 610 20.1 665 16.0
LMM 201 8.4 480 10.7 296 9.8 543 13.1
Other/unspecified 551 23.0 614 13.7 698 23.0 579 14.0
Tumor localization .003 <.001
Head/ neck 710 29.6 1221 27.2 699 23.1 900 21.7
Trunk 952 39.7 1943 43.2 407 13.4 713 17.2
Upper limbs 423 17.7 838 18.7 802 26.5 1170 28.2
Lower limbs 300 12.5 480 10.7 1116 36.8 1357 32.7
Unknown 12 0.5 12 0.3 7 0.2 10 0.2
Subgroup analysis
Number of comorbiditiesa <.001 <.001
None 97 33.1 82 15.5 143 40.5 128 26.5
1 73 24.9 129 24.4 101 28.6 135 28.0
2 107 36.5 267 50.5 92 26.1 154 31.9
Unknown 16 5.5 51 9.6 17 4.8 66 13.7
aData only available for a subgroup of the total study population (n¼ 1658, 12% of total study population).
Abbreviations: IQR: interquartile range; LMM: lentigo maligna melanoma; NM: nodular melanoma; SSM: superficial spreading melanoma.
Figure 2. Annual median Breslow thickness by year, sex and age category (2003–2015).






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































For subgroup analyses, we added comorbidity to the
models, this resulted in similar associations between the
prognostic factors and survival as observed in the models
without co-morbidity (data not shown).
Discussion
Incidence of melanoma is increasing in all age categories.
However, a disproportional increase is seen among the eld-
erly, particularly among older men. They have shown a
nearly 6-fold increase in incidence since 1989. This unfavor-
able trend among older men is in accordance with observa-
tions from other countries [17–19].
A possible explanation for the disproportional increase in
incidence among older people (men) is that they gained less
advantage of public health campaigns compared to younger
people. A recent study in Australia showed stabilizing and
falling trends in incidence among young people, but not yet
in the elderly (aged > 60 years). A comparison of birth
cohorts revealed that the largest decline in age-specific mel-
anoma incidence rates was seen in the cohorts that were
raised after the introduction of public health campaigns and
thus grew up with greater awareness of melanoma risk com-
pared to earlier birth cohorts [19]. An explanation for the
higher susceptibility to melanoma of particularly older men
might be a higher lifetime UV exposure (more total time
spent outdoors), combined with poorer sun protection
behaviours [20,21].
In the Netherlands, public health campaigns aimed at
increasing awareness of skin cancer started in the late 1980s.
While it may be too early to see a levelling-off or decrease in
incidence in the older age categories yet, it may have
resulted in an increased awareness of the signs and symp-
toms of melanoma, and subsequently an earlier detection.
Older patients are still diagnosed with thicker melanomas.
However, median Breslow thickness has decreased consider-
ably during the recent years, particularly among older
patients. This may suggest that, regarding melanoma aware-
ness, older people (particularly men) are catching up with
younger people. A previous study concluded that it seems
likely that overdiagnosis of thin lesions contributed to the
increasing trends in melanoma incidence rates in
the Netherlands [22]. This may also partly be the case for the
older patients in our study. Due to more awareness, possibly
more (thin) melanomas were detected and treated, which
would not have resulted in morbidity and mortality other-
wise. However, analyses stratified by Breslow thickness
showed a rising incidence of all (thin (<2mm), intermediate-
thickness (2–4mm), and thick (4mm)) melanomas in older
patients during 2003–2015 (data not shown). This suggests
that the increasing melanoma incidence among older people
is not entirely due to overdiagnosis, even though the results
confirmed that incidence of thin melanomas increased
most rapidly.
The gap in median Breslow thickness between the
younger and older patients declined, particularly because of
the decreasing Breslow thickness among older patients. This
observation is in contrast with an earlier study among Dutch
melanoma patients, reporting a less prominent decline in
Breslow thickness among older patients than among younger
patients [23]. Nonetheless, in contrast with this previous
study, we used a continuous measure of Breslow thickness
(median), instead of a categorical variable, and included a
more recent time period (1994–2008 versus 2003–2015),
which may explain the different results.
Besides a declining gap in Breslow thickness between
younger and older patients, also disparities in RS declined
over time. This seems related. Both in younger and older
patients, we observed an increase in survival. But also here,
the largest improvements are seen in the elderly. Survival of
older men, who had the lowest survival, improved the most.
However, multivariable analyses revealed that the effect
of period of diagnosis on survival (a lower excess mortality
in the more recent time period) disappeared after correction
for Breslow thickness in older patients, adding other prog-
nostic variables to the model did not alter the association
between period of diagnosis and survival. This confirms that
the improved survival in older patients over time can largely
be ascribed to the increased detection of thinner melano-
mas. Contrary, in younger patients changes in Breslow thick-
ness could not explain the lower mortality seen over time.
Recent introductions of effective systemic therapies (i.e.,
BRAF/MEK inhibitors and/or immune checkpoint blockade)
may have contributed to an improved survival in younger
patients, while older patients less often received
those treatments.
Besides thicker melanomas, we also observed that older
patients more often had other poor prognostic features.
Similar to results of prior studies, elderly were more often
diagnosed with nodular melanomas and truncal or head and
neck melanomas [6,8,24–26].
Although the gap in survival between younger and older
patients is declining, differences still exist. Multiple factors
may contribute to a later detection in the older age catego-
ries. For example, a lower risk awareness, the lack of a
spouse, the presence of comorbidities, cognitive and visual
impairments which may complicate early (self-) detection
and more nodular melanomas which develop de novo and
very quickly. Furthermore, various studies indicated subopti-
mal staging and/or treatment in older patients which may
also have contributed to a poorer prognosis [8,27].
Stage-specific survival indicated that older patients have a
worse prognosis compared to their younger counterparts
when diagnosed with stage II, III or an unknown stage mel-
anoma at time of diagnosis. A reason for this difference
might be the higher recurrence rate and shorter time to
recurrences, possibly related to a weakened immune system
in older patients, and/or to less optimal staging (understag-
ing) or treatment of older patients [6,27,28].
We did not observe a survival disadvantage for older
patients with thin melanomas (stage I) or for patients with
distant metastasis at time of diagnosis (stage IV). Both
younger and older patients with thin melanomas have a
high likelihood of cure, and low rate of local and distant
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recurrences. Consequently, survival was similar to, or even
slightly exceeded, the survival of the general population in
both groups. Prognosis of patients with distant metastases
(stage IV) was almost equally poor in younger and elderly
patients. Therapeutic options were limited for most of those
patients, since the vast majority of the patients in our study
was diagnosed before new therapies (targeted therapies and
immunotherapy) became widely available for advanced
stage melanoma.
Our data, however, was limited to stage at diagnosis and
we cannot draw conclusions for survival differences in
patients with later disease progression.
Details on novel therapies are currently under investiga-
tion in the Dutch Melanoma Treatment Registry (DMTR) [29].
While studies have shown that new therapies improved sur-
vival [30–34], they are also associated with potentially severe
adverse events [32–34]. Considering the large number of
older patients and the heterogeneity of the elderly popula-
tion with regard to frailty and comorbidities, it is of import-
ance to have a representative proportion of elderly patients
included in clinical trials, and to monitor how older patients
respond to the new modalities. This, to gain knowledge
about how they can handle new treatment modalities and
benefit optimally from them. First results indicate that elderly
less often received new therapies, but that those who are
treated show similar responses as their younger counterparts
[35,36]. During the latter years of our study period, we
indeed saw that with advancing age a lower number of
patients with metastatic melanoma (at initial diagnosis) was
treated with targeted therapy or immunotherapy. During
2013–2015, 54% (n¼ 52) of the patients aged <70 years ver-
sus 17% (n¼ 4) when aged 80 years (data not shown) was
initially treated with one of the new treatment options.
Unfortunately, the number of patients was too small for fur-
ther analyses.
Our study has several limitations. Due to the observational
nature of the study, complete information on some major
prognostic factors (such as mitotic rate and tumor ulceration)
was only available for more recent years, and could not be
included in the time trends study. Strengths of this study are
its nationwide character (comprehensive full coverage), the
large number of patients included, and the complete follow-
up with regard to vital status.
Summarized, the gap in incidence of melanoma between
younger and elderly patients is increasing while disparities in
survival are declining. The most prominent changes over
time were seen in older men. They showed the strongest
increase in incidence, while their survival improved the most.
The Breslow thickness of elderly patients decreased con-
siderably, explaining the declining gap in survival between
the younger and elderly melanoma patients. Nonetheless,
elderly melanoma patients still have a survival disadvantage,
and their incidence is rising more rapidly compared to
younger patients.
The treatment landscape is changing for melanoma
patients, also for the elderly. Therefore, it is of importance to
stay attentive on melanoma in the elderly to allow them to
benefit optimally from those advances.
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